Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

OBJECTIVE: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between obje...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Liver Cancer
Autores principales: Kudo, Masatoshi, Ueshima, Kazuomi, Chiba, Yasutaka, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Arai, Yasuaki
Formato: Artigo
Lenguaje:Inglês
Publicado: S. Karger AG 2019
Materias:
Original Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883462/
https://ncbi.nlm.nih.gov/pubmed/31799207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503032
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares